Gastrointestinal Cancer Clinical Trial Sentiment
Hear what key opinion leaders such as Dr. Pashtoon Kasi, Dr. Joseph McCollom, Dr. Allyson Ocean, Dr. Nina Sanford, Dr. Mark Lewis and others are saying about the results of the most recent gastrointestinal cancer clinical trials.
CheckMate 9DW
CheckMate 9DW is a phase III trial evaluating nivolumab (Opdivo) plus ipilimumab (Yervoy) as a first-line treatment for patients with advanced heptocellular carcinoma (HCC) who have not received prior systemic therapy. The primary endpoint of overall survival was recently met in the CheckMate 9DW clinical trial.
Read more
BESPOKE
BESPOKE is a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. The clinical trial is led by Dr. Pashtoon Kasi from Weill Cornell Medicine and New Your Presbyterian Hospital.
Read more
COBRA
COBRA is a phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer. Dr. Van Morris from MD Anderson Cancer Center recently presented the results of the COBRA trial at the ASCO #GI24 Medical Conference.
Read more
IMbrave151
IMbrave151 is a phase II study of atezolizumab (Tecentriq) with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer. Dr. Anthony El-Khoueiry of Keck Medicine at USC recently presented the trial results at ASCO #GI24.
Read more
EMERALD-1
EMERALD-1 is a phase III study of transarterial chemoembolization combined with durvalumab (Imfinzi) with or without bevacizumab in patients with unresectable hepatocellular carcinoma eligible for embolization. Dr. Riccardo Lencioni of the University of Pisa School of Medicine presented results at ASCO #GI24.
Read more
NAPOLI-3
A randomized, open-label phase III study of liposomal irinotecan (Onivyde) + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma. Dr. Eileen O'Reilly of Memorial Sloan Kettering presented the results of #ASCO23.
Read more
NETTER-2
NETTER-2 is a phase III study evaluating lutetium Lu-177 Dotatate (Lutathera) for advanced gastroenteropancreatic neuroendocrine tumors. Dr. Simron Singh, Sunnybrook Odette Cancer Center, University of Toronto, Toronto, ON, presented NETTER-2 at ASCO #GI24.
Read more
SKYSCRAPER-08
SKYSCRAPER-08 is a phase III study of first-line tiragolumab + atezolizumab (Tecentriq) and chemotherapy in patients with esophageal squamous cell carcinoma. Dr. Chih-Hung Hsu, from National Taiwan University Hospital in Taipei, Taiwan, presented the trial at ASCO #GI24.
Read more